Werner Hacke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11664898/publications.pdf

Version: 2024-02-01

291	68,931	98	257
papers	citations	h-index	g-index
293	293	293	31375
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 883-891.	27.0	8,006
2	Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. New England Journal of Medicine, 2008, 359, 1317-1329.	27.0	5,749
3	Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke. New England Journal of Medicine, 2015, 372, 2285-2295.	27.0	4,255
4	Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet, The, 1998, 352, 1245-1251.	13.7	3,216
5	Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. New England Journal of Medicine, 2006, 354, 1706-1717.	27.0	2,582
6	Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet, The, 2007, 369, 275-282.	13.7	2,527
7	Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet, The, 2004, 363, 768-774.	13.7	2,316
8	Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric Stroke. JAMA - Journal of the American Medical Association, 1995, 274, 1017.	7.4	2,148
9	Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet, The, 2014, 384, 1929-1935.	13.7	1,971
10	Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet, The, 2010, 375, 1695-1703.	13.7	1,871
11	Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurology, The, 2007, 6, 215-222.	10.2	1,580
12	'Malignant' Middle Cerebral Artery Territory Infarction. Archives of Neurology, 1996, 53, 309.	4.5	1,291
13	Recommendations on Angiographic Revascularization Grading Standards for Acute Ischemic Stroke. Stroke, 2013, 44, 2650-2663.	2.0	1,264
14	The Desmoteplase in Acute Ischemic Stroke Trial (DIAS). Stroke, 2005, 36, 66-73.	2.0	980
15	Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Annals of Neurology, 1992, 32, 78-86.	5.3	970
16	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2015, 17, 1467-1507.	1.7	951
17	Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY). Stroke, 2007, 38, 2518-2525.	2.0	784
18	The Heidelberg Bleeding Classification. Stroke, 2015, 46, 2981-2986.	2.0	755

#	Article	IF	Citations
19	Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial. Journal of the American College of Cardiology, 2007, 49, 1982-1988.	2.8	752
20	European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2013, 15, 625-651.	1.7	721
21	Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion–diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurology, The, 2009, 8, 141-150.	10.2	526
22	Thrombolysis with alteplase 3–4·5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet, The, 2008, 372, 1303-1309.	13.7	514
23	Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS). Stroke, 2006, 37, 1227-1231.	2.0	511
24	Hemorrhagic Transformation of Ischemic Brain Tissue. Stroke, 2001, 32, 1330-1335.	2.0	508
25	Hemicraniectomy in Older Patients with Extensive Middle-Cerebral-Artery Stroke. New England Journal of Medicine, 2014, 370, 1091-1100.	27.0	494
26	Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation. Circulation, 2013, 127, 224-232.	1.6	463
27	Stroke Magnetic Resonance Imaging Is Accurate in Hyperacute Intracerebral Hemorrhage. Stroke, 2004, 35, 502-506.	2.0	409
28	Effect of Conscious Sedation vs General Anesthesia on Early Neurological Improvement Among Patients With Ischemic Stroke Undergoing Endovascular Thrombectomy. JAMA - Journal of the American Medical Association, 2016, 316, 1986.	7.4	402
29	Multivariable Analysis of Outcome Predictors and Adjustment of Main Outcome Results to Baseline Data Profile in Randomized Controlled Trials. Stroke, 2008, 39, 3316-3322.	2.0	397
30	Recommendations for the Management of Intracranial Haemorrhage – Part I: Spontaneous Intracerebral Haemorrhage. Cerebrovascular Diseases, 2006, 22, 294-316.	1.7	393
31	Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry. PLoS ONE, 2013, 8, e63479.	2.5	375
32	Decompressive surgery in space-occupying hemispheric infarction. Critical Care Medicine, 1995, 23, 1576-1587.	0.9	367
33	Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stroke: Results of an International Phase III Trial. Stroke, 2008, 39, 87-99.	2.0	362
34	EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summaryâ€. European Heart Journal, 2013, 34, 2094-2106.	2.2	356
35	Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014. 130. 138-146.	1.6	345
36	A Standardized MRI Stroke Protocol. Stroke, 1999, 30, 765-768.	2.0	328

3

#	Article	IF	Citations
37	Early Prediction of Irreversible Brain Damage after Ischemic Stroke at CT. Radiology, 2001, 219, 95-100.	7.3	325
38	Extending thrombolysis to 4·5–9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data. Lancet, The, 2019, 394, 139-147.	13.7	321
39	Intraventricular Brain-Derived Neurotrophic Factor Reduces Infarct Size after Focal Cerebral Ischemia in Rats. Journal of Cerebral Blood Flow and Metabolism, 1997, 17, 500-506.	4.3	314
40	Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurology, The, 2012, 11, 315-322.	10.2	310
41	Stroke treatment with alteplase given 3·0–4·5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurology, The, 2009, 8, 1095-1102.	10.2	303
42	Mechanical thrombectomy in acute ischemic stroke: Consensus statement by ESO-Karolinska Stroke Update 2014/2015, supported by ESO, ESMINT, ESNR and EAN. International Journal of Stroke, 2016, 11, 134-147.	5.9	303
43	Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurology, The, 2016, 15, 566-573.	10.2	296
44	Imaging-Based Decision Making in Thrombolytic Therapy for Ischemic Stroke. Stroke, 2003, 34, 575-583.	2.0	287
45	Endovascular stent thrombectomy: the new standard of care for large vessel ischaemic stroke. Lancet Neurology, The, 2015, 14, 846-854.	10.2	280
46	Early recanalisation in acute ischaemic stroke saves tissue at risk defined by MRI. Lancet, The, 1999, 353, 2036-2037.	13.7	270
47	Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. European Heart Journal, 2015, 36, 288-296.	2.2	266
48	Controlled Safety Study of a Hemoglobin-Based Oxygen Carrier, DCLHb, in Acute Ischemic Stroke. Stroke, 1999, 30, 993-996.	2.0	256
49	Effects of Hypertonic Saline Hydroxyethyl Starch Solution and Mannitol in Patients With Increased Intracranial Pressure After Stroke. Stroke, 1998, 29, 1550-1555.	2.0	249
50	World Stroke Organization (WSO): Global Stroke Fact Sheet 2019. International Journal of Stroke, 2019, 14, 806-817.	5.9	249
51	Effectiveness and Safety of Transcranial Laser Therapy for Acute Ischemic Stroke. Stroke, 2009, 40, 1359-1364.	2.0	247
52	Ultrastructural connective tissue abnormalities in patients with spontaneous cervicocerebral artery dissections. Annals of Neurology, 1998, 44, 281-285.	5.3	242
53	Predicting Long-Term Outcome After Acute Ischemic Stroke. Stroke, 2008, 39, 1821-1826.	2.0	242
54	Comparison of CT and CT Angiography Source Images With Diffusion-Weighted Imaging in Patients With Acute Stroke Within 6 Hours After Onset. Stroke, 2002, 33, 2426-2432.	2.0	241

#	Article	IF	Citations
55	Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial. Journal of the American College of Cardiology, 2013, 61, 1998-2006.	2.8	240
56	Outcome and Symptomatic Bleeding Complications of Intravenous Thrombolysis Within 6 Hours in MRI-Selected Stroke Patients. Stroke, 2006, 37, 852-858.	2.0	235
57	Stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia. Annals of Neurology, 2001, 49, 460-469.	5.3	227
58	MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. Lancet Neurology, The, 2006, 5, 661-667.	10.2	227
59	Bleeding Complications With Dual Antiplatelet Therapy Among Patients With Stable Vascular Disease or Risk Factors for Vascular Disease. Circulation, 2010, 121, 2575-2583.	1.6	218
60	Factors Associated With Major Bleeding Events. Journal of the American College of Cardiology, 2014, 63, 891-900.	2.8	212
61	Role of CT Angiography in Patient Selection for Thrombolytic Therapy in Acute Hemispheric Stroke. Stroke, 1998, 29, 935-938.	2.0	210
62	Correlation of imaging and histopathology of thrombi in acute ischemic stroke with etiology and outcome: a systematic review. Journal of NeuroInterventional Surgery, 2017, 9, 529-534.	3.3	208
63	Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. European Heart Journal, 2017, 38, ehw058.	2.2	203
64	Preventing dementia by preventing stroke: The Berlin Manifesto. Alzheimer's and Dementia, 2019, 15, 961-984.	0.8	200
65	Monitoring Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis for Acute Ischemic Stroke With Diffusion and Perfusion MRI. Stroke, 2000, 31, 1318-1328.	2.0	195
66	International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). American Heart Journal, 2012, 163, 13-19.e1.	2.7	195
67	Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes. Stroke, 2016, 47, 2373-2379.	2.0	193
68	Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban. Stroke, 2014, 45, 1304-1312.	2.0	187
69	Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. Lancet Neurology, The, 2016, 15, 925-933.	10.2	187
70	Contemporary Outcome Measures in Acute Stroke Research. Stroke, 2012, 43, 1163-1170.	2.0	183
71	Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 61, 651-658.	2.8	181
72	Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial. Journal of the American Heart Association, 2013, 2, e000067.	3.7	179

#	Article	IF	Citations
73	Effect and Feasibility of Controlled Rewarming After Moderate Hypothermia in Stroke Patients With Malignant Infarction of the Middle Cerebral Artery. Stroke, 2001, 32, 2833-2835.	2.0	168
74	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. American Heart Journal, 2017, 194, 132-140.	2.7	161
75	Ischemic core and hypoperfusion volumes predict infarct size in <scp>SWIFT PRIME</scp> . Annals of Neurology, 2016, 79, 76-89.	5. 3	155
76	Mismatch-Based Delayed Thrombolysis. Stroke, 2010, 41, e25-33.	2.0	154
77	Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. European Heart Journal, 2014, 35, 3377-3385.	2.2	154
78	Prognosis of Stroke Patients Requiring Mechanical Ventilation in a Neurological Critical Care Unit. Stroke, 1997, 28, 711-715.	2.0	152
79	The Stroke–Thrombolytic Predictive Instrument. Stroke, 2006, 37, 2957-2962.	2.0	148
80	Decompressive Craniectomy for Cerebral Infarction. Stroke, 1995, 26, 259-264.	2.0	146
81	Endovascular Stroke Therapy. Stroke, 2013, 44, 1453-1455.	2.0	145
82	Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. European Heart Journal, 2014, 35, 1873-1880.	2.2	145
83	Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial. Stroke, 2014, 45, 1739-1747.	2.0	142
84	Facilities Available in European Hospitals Treating Stroke Patients. Stroke, 2007, 38, 2985-2991.	2.0	141
85	Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. Circulation, 2016, 133, 352-360.	1.6	141
86	Evidence-Based Guidelines for the Management of Large Hemispheric Infarction. Neurocritical Care, 2015, 22, 146-164.	2.4	133
87	The ECASS 3-Hour Cohort. Cerebrovascular Diseases, 1998, 8, 198-203.	1.7	130
88	Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). American Heart Journal, 2015, 170, 675-682.e8.	2.7	128
89	Analyses of thrombi in acute ischemic stroke: A consensus statement on current knowledge and future directions. International Journal of Stroke, 2017, 12, 606-614.	5.9	128
90	Cause of Death and Predictors of Allâ€Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. Journal of the American Heart Association, 2016, 5, e002197.	3.7	127

#	Article	IF	CITATIONS
91	Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Disease. Circulation, 2009, 120, 2337-2344.	1.6	123
92	Challenging the Ischemic Core Concept in Acute Ischemic Stroke Imaging. Stroke, 2020, 51, 3147-3155.	2.0	122
93	DESTINY II: Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery II. International Journal of Stroke, 2011, 6, 79-86.	5. 9	120
94	Dichotomized Efficacy End Points and Global End-Point Analysis Applied to the ECASS Intention-to-Treat Data Set. Stroke, 1998, 29, 2073-2075.	2.0	119
95	Stroke Neurologist's Perspective on the New Endovascular Trials. Stroke, 2015, 46, 1447-1452.	2.0	116
96	Cost-Effectiveness of Solitaire Stent Retriever Thrombectomy for Acute Ischemic Stroke. Stroke, 2017, 48, 379-387.	2.0	115
97	Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data. Lancet, The, 2020, 396, 1574-1584.	13.7	107
98	Shift Analysis Versus Dichotomization of the Modified Rankin Scale Outcome Scores in the NINDS and ECASS-II Trials. Stroke, 2007, 38, 3205-3212.	2.0	105
99	Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation. Circulation: Heart Failure, 2013, 6, 740-747.	3.9	102
100	Priorities to reduce the burden of stroke in Latin American countries. Lancet Neurology, The, 2019, 18, 674-683.	10.2	102
101	Superoxide Dismutase Activity in Serum of Patients With Acute Cerebral Ischemic Injury. Stroke, 1997, 28, 2425-2428.	2.0	102
102	The Virtual International Stroke Trials Archive. Stroke, 2007, 38, 1905-1910.	2.0	101
103	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open, 2017, 7, e017157.	1.9	92
104	Transcranial Laser Therapy in Acute Stroke Treatment. Stroke, 2014, 45, 3187-3193.	2.0	89
105	Thrombolytic therapy for ischemic stroke—A review. Part II—Intra-arterial thrombolysis, vertebrobasilar stroke, phase IV trials, and stroke imaging. Critical Care Medicine, 2001, 29, 1819-1825.	0.9	88
106	Acute Stroke Imaging Research Roadmap III Imaging Selection and Outcomes in Acute Stroke Reperfusion Clinical Trials. Stroke, 2016, 47, 1389-1398.	2.0	88
107	The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. European Heart Journal, 2012, 33, 2143-2150.	2.2	86
108	Acute Treatment of Ischemic Stroke. Cerebrovascular Diseases, 2000, 10, 22-33.	1.7	85

#	Article	IF	CITATIONS
109	Extending the time window for intravenous thrombolysis in acute ischemic stroke using magnetic resonance imaging-based patient selection. International Journal of Stroke, 2019, 14, 483-490.	5.9	82
110	Plasma Insulin-like Growth Factor I and IGF Binding Protein 3 Levels in Patients With Acute Cerebral Ischemic Injury. Stroke, 1997, 28, 1744-1748.	2.0	82
111	Time to treatment with recombinant tissue plasminogen activator and outcome of stroke in clinical practice: retrospective analysis of hospital quality assurance data with comparison with results from randomised clinical trials. BMJ, The, 2014, 348, g3429-g3429.	6.0	81
112	Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. European Heart Journal, 2014, 35, 233-241.	2.2	81
113	Measuring Outcomes as a Function of Baseline Severity of Ischemic Stroke. Cerebrovascular Diseases, 2004, 18, 124-129.	1.7	80
114	Point-of-Care International Normalized Ratio Testing Accelerates Thrombolysis in Patients With Acute Ischemic Stroke Using Oral Anticoagulants. Stroke, 2009, 40, 3547-3551.	2.0	80
115	Sedation vs. Intubation for Endovascular Stroke TreAtment (SIESTA) – A Randomized Monocentric Trial. International Journal of Stroke, 2015, 10, 969-978.	5.9	80
116	Improved Prediction of Poor Outcome After Thrombolysis Using Conservative Definitions of Symptomatic Hemorrhage. Stroke, 2012, 43, 240-242.	2.0	78
117	Thrombolytic therapy for ischemic stroke—A review. Part l—Intravenous thrombolysis. Critical Care Medicine, 2001, 29, 1812-1818.	0.9	76
118	Development, Expansion, and Use of a Stroke Clinical Trials Resource for Novel Exploratory Analyses. International Journal of Stroke, 2012, 7, 133-138.	5.9	75
119	Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. European Heart Journal Quality of Care & Discrete Clinical Outcomes, 2019, 5, 145-152.	4.0	75
120	Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients) Tj ETQq0 0 0 rgBT	Overlock	2 10 Tf 50 31 74
121	Effect of Clopidogrel plus ASA vs. ASA Early after TIA and Ischaemic Stroke: A Substudy of the CHARISMA Trial. International Journal of Stroke, 2011, 6, 3-9.	5.9	73
122	Pretreatment Blood–Brain Barrier Damage and Post-Treatment Intracranial Hemorrhage in Patients Receiving Intravenous Tissue-Type Plasminogen Activator. Stroke, 2014, 45, 2030-2035.	2.0	73
123	Spontaneous Resolution of a Large Spinal Epidural Hematoma: Case Report. Neurosurgery, 1996, 38, 816-818.	1.1	71
124	European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits ECASS-4: ExTEND. International Journal of Stroke, 2016, 11, 260-267.	5.9	69
125	An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. European Heart Journal, 2007, 28, 2200-2207.	2.2	68
126	Acute Treatment of Ischaemic Stroke. Cerebrovascular Diseases, 2004, 17, 30-46.	1.7	64

#	Article	IF	CITATIONS
127	Analysis of Nationwide Stroke Patient Care in Times of COVID-19 Pandemic in Germany. Stroke, 2021, 52, 716-721.	2.0	62
128	Hemicraniectomy with dural augmentation in medically uncontrollable hemispheric infarction. Neurosurgical Focus, 1997, 2, E7.	2.3	61
129	Infection-Associated Cervical Artery Dissection. Stroke, 1997, 28, 453-455.	2.0	60
130	Management of Acute Stroke in Patients Taking Novel Oral Anticoagulants. International Journal of Stroke, 2014, 9, 627-632.	5.9	58
131	Endovascular Therapy in Acute Ischemic Stroke. Stroke, 2016, 47, 548-553.	2.0	57
132	Age and Sex Differences in Ischemic Stroke Treatment in a Nationwide Analysis of 1.11 Million Hospitalized Cases. Stroke, 2019, 50, 3494-3502.	2.0	57
133	Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. Heart Rhythm, 2014, 11, 925-932.	0.7	52
134	Surgical Decompression for Space-Occupying Hemispheric Infarction. JAMA Neurology, 2021, 78, 208.	9.0	52
135	An update on thrombolytic therapy for acute stroke. Current Opinion in Neurology, 2004, 17, 69-77.	3.6	51
136	Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. American Heart Journal, 2016, 179, 77-86.	2.7	51
137	Remote or Extraischemic Intracerebral Hemorrhageâ€"An Uncommon Complication of Stroke Thrombolysis. Stroke, 2014, 45, 1657-1663.	2.0	50
138	Clinical review: Therapy for refractory intracranial hypertension in ischaemic stroke. Critical Care, 2007, 11, 231.	5.8	48
139	Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy. Annals of Internal Medicine, 2013, 158, 861.	3.9	46
140	Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. Europace, 2015, 17, 1007-1017.	1.7	46
141	Bedside monitoring of cerebral blood flow in patients with acute hemispheric stroke. Critical Care Medicine, 2000, 28, 511-516.	0.9	45
142	Hemicraniotomy in Space-Occupying Hemispheric Infarction: Useful Early Intervention or Desperate Activism?. Cerebrovascular Diseases, 1996, 6, 325-329.	1.7	43
143	Treatment of Acute Ischemic Stroke. Circulation, 2002, 106, 1563-1569.	1.6	42
144	Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. American Heart Journal, 2011, 162, 98-105.e1.	2.7	41

#	Article	IF	CITATIONS
145	Door-to-Needle Time and the Proportion of Patients Receiving Intravenous Thrombolysis in Acute Ischemic Stroke. Stroke, 2013, 44, 3249-3253.	2.0	40
146	Standards of practice in acute ischemic stroke intervention: international recommendations. Journal of NeuroInterventional Surgery, 2018, 10, 1121-1126.	3.3	40
147	End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 470-478.	2.2	39
148	Managing reversal of direct oral anticoagulants in emergency situations. Thrombosis and Haemostasis, 2016, 116, 1003-1010.	3.4	39
149	Recurrence of cervical artery dissection. Neurology, 2018, 90, e1372-e1378.	1.1	38
150	Distribution and evolution of acute interventional ischemic stroke treatment in Germany from 2010 to 2016. Neurological Research and Practice, 2019, 1, 4.	2.0	38
151	Intensive Care of Acute Ischemic Stroke. Cerebrovascular Diseases, 1994, 4, 385-392.	1.7	36
152	Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. Heart, 2016, 102, 1036-1043.	2.9	36
153	Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials. International Journal of Stroke, 2018, 13, 175-189.	5.9	36
154	Relationship Between Onset-to-Door Time and Door-to-Thrombolysis Time. Stroke, 2013, 44, 2808-2813.	2.0	35
155	European Stroke Facilities Survey: The German and Austrian Perspective. Cerebrovascular Diseases, 2009, 27, 138-145.	1.7	34
156	Predicting major bleeding in patients with noncardioembolic stroke on antiplatelets. Neurology, 2017, 89, 936-943.	1.1	34
157	Herpes simplex virus encephalitis: chronic progressive cerebral MRI changes despite good clinical recovery and low viral load - an experimental mouse study. European Journal of Neurology, 1999, 6, 531-538.	3.3	33
158	From CURE to MATCH: ADP Receptor Antagonists as the Treatment of Choice for High-Risk Atherothrombotic Patients. Cerebrovascular Diseases, 2002, 13, 22-26.	1.7	33
159	Pointâ€ofâ€care reversal treatment in phenprocoumonâ€related intracerebral hemorrhage. Annals of Neurology, 2010, 67, 788-793.	5.3	33
160	Alteplase for Acute Ischemic Stroke in Patients Aged >80 Years. Stroke, 2020, 51, 2322-2331.	2.0	33
161	Treatment of Acute Ischemic Stroke. Circulation, 2002, 106, 1736-1740.	1.6	32
162	Baroreflex Sensitivity to Predict Malignant Middle Cerebral Artery Infarction. Stroke, 2012, 43, 714-719.	2.0	32

#	Article	IF	Citations
163	Interventional Thrombectomy for Major Stroke â€" A Step in the Right Direction. New England Journal of Medicine, 2015, 372, 76-77.	27.0	32
164	Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF. Europace, 2016, 18, 1135-1142.	1.7	31
165	A New DAWN for Imaging-Based Selection in the Treatment of Acute Stroke. New England Journal of Medicine, 2018, 378, 81-83.	27.0	31
166	Pure Motor Hemiparesis with Stable Somatosensory Evoked Potential Monitoring during Aneurysm Surgery. Neurosurgery, 1992, 31, 145-150.	1.1	30
167	Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin. Circulation, 2017, 135, 1001-1003.	1.6	30
168	Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. Blood Advances, 2021, 5, 1081-1091.	5.2	30
169	Healthy Life-Year Costs of Treatment Speed From Arrival to Endovascular Thrombectomy in Patients With Ischemic Stroke. JAMA Neurology, 2021, 78, 709.	9.0	30
170	State of Acute Endovascular Therapy. Stroke, 2015, 46, 1727-1734.	2.0	29
171	Circulatory and Respiratory Parameters during Acute Endovascular Stroke Therapy in Conscious Sedation or General Anesthesia. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 1244-1249.	1.6	28
172	Can Multivariable Risk-Benefit Profiling Be Used to Select Treatment-Favorable Patients for Thrombolysis in Stroke in the 3- to 6-Hour Time Window?. Stroke, 2006, 37, 2963-2969.	2.0	26
173	Thrombolysis with alteplase for acute ischemic stroke: review of SITS-MOST and other Phase IV studies. Expert Review of Neurotherapeutics, 2007, 7, 783-788.	2.8	26
174	Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Stroke in Patients with a History of Atrial Fibrillation: Subgroup Analysis of the CHARISMA Randomized Trial. Cerebrovascular Diseases, 2008, 25, 344-347.	1.7	26
175	Restriction of therapy mainly explains lower thrombolysis rates in reduced stroke service levels. Neurology, 2016, 86, 1975-1983.	1.1	26
176	Thrombolysis for acute stroke under antiplatelet therapy: safe enough to be beneficial?. Nature Clinical Practice Neurology, 2008, 4, 474-475.	2.5	25
177	Decompressive Surgery for Severe Brain Edema. Journal of Intensive Care Medicine, 2009, 24, 168-178.	2.8	25
178	Antiplatelet Therapy After Noncardioembolic Stroke. Stroke, 2019, 50, 1812-1818.	2.0	25
179	Select wisely: the ethical challenge of defining large core with perfusion in the early time window. Journal of NeuroInterventional Surgery, 2021, 13, 497-499.	3.3	25
180	Jugular Venous Oxygen Saturation Thresholds in Trauma Patients May Not Extrapolate to Ischemic Stroke Patients. Journal of Neurosurgical Anesthesiology, 2002, 14, 130-136.	1.2	24

#	Article	IF	Citations
181	Design of future acute-stroke treatment trials. Lancet Neurology, The, 2003, 2, 54-61.	10.2	24
182	Deep learning-based detection and segmentation of diffusion abnormalities in acute ischemic stroke. Communications Medicine, $2021,1,.$	4.2	24
183	Stroke Treatment Academic Industry Roundtable. Stroke, 2013, 44, 3596-3601.	2.0	23
184	Ultra-Early Intravenous Stroke Thrombolysis. Stroke, 2013, 44, 2913-2916.	2.0	23
185	A full year of the COVIDâ€19 pandemic with two infection waves and its impact on ischemic stroke patient care in Germany. European Journal of Neurology, 2022, 29, 105-113.	3.3	23
186	Effect of Clopidogrel on the Rate and Functional Severity of Stroke Among High Vascular Risk Patients. Stroke, 2010, 41, 1679-1683.	2.0	22
187	Frequency of Increased Blood Pressure Levels During Systemic Thrombolysis and Risk of Intracerebral Hemorrhage. Stroke, 2011, 42, 1702-1706.	2.0	22
188	Acute ischemic stroke care in Germany – further progress from 2016 to 2019. Neurological Research and Practice, 2021, 3, 14.	2.0	22
189	Oral Anticoagulants – A Frequent Challenge for the Emergency Management of Acute Ischemic Stroke. Cerebrovascular Diseases, 2012, 34, 411-418.	1.7	21
190	Effect of General Anesthesia versus Conscious Sedation for Stroke Thrombectomy on Angiographic Workflow in a Randomized Trial: A Post Hoc Analysis of the SIESTA Trial. Radiology, 2018, 286, 1016-1021.	7.3	20
191	Fast Point-of-Care Coagulometer Guided Reversal of Oral Anticoagulation at the Bedside Hastens Management of Acute Subdural Hemorrhage. Neurocritical Care, 2010, 13, 321-325.	2.4	19
192	Early Decompressive Hemicraniectomy in Older Patients With Nondominant Hemispheric Infarction Improves Outcome. Stroke, 2011, 42, 843-844.	2.0	19
193	Fast-Track Intubation for Accelerated Interventional Stroke Treatment. Neurocritical Care, 2012, 17, 354-360.	2.4	19
194	Haemorrhage and hemicraniectomy. Current Opinion in Neurology, 2015, 28, 16-22.	3.6	19
195	Standards of Practice in Acute Ischemic Stroke Intervention: International Recommendations. American Journal of Neuroradiology, 2018, 39, E112-E117.	2.4	19
196	GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. Future Cardiology, 2021, 17, 19-38.	1.2	19
197	Surgical Decompression of Patients With Large Middle Cerebral Artery Infarcts Is Effective. Stroke, 2003, 34, 2304-2305.	2.0	18
198	Hemicraniectomy in the management of space-occupying ischemic stroke. Journal of Clinical Neuroscience, 2013, 20, 6-12.	1.5	18

#	Article	IF	CITATIONS
199	HeadPoST. Neurology, 2018, 90, 885-889.	1.1	18
200	Indomethacin for Brain Edema following Stroke. Cerebrovascular Diseases, 1999, 9, 248-250.	1.7	17
201	Stroke. Annals of Emergency Medicine, 2001, 37, S137-S144.	0.6	17
202	Deep brain stimulation to reduce sexual drive. Journal of Psychiatry and Neuroscience, 2015, 40, 429-431.	2.4	17
203	Inpatient TIA and stroke care in adult patients in Germany - retrospective analysis of nationwide administrative data sets of 2011 to 2017. Neurological Research and Practice, 2019, 1, 39.	2.0	16
204	Recanalization Devices Should Be Restricted to Clinical Trials. Stroke, 2010, 41, 191-193.	2.0	15
205	Treatment of Acute Ischemic Stroke With Clot Retrieval Devices. Current Treatment Options in Cardiovascular Medicine, 2012, 14, 260-272.	0.9	15
206	Thrombectomy in Patients Ineligible for iv tPA (THRILL). International Journal of Stroke, 2015, 10, 950-955.	5.9	15
207	Access, timing and frequency of very early stroke rehabilitation – insights from the Baden-Wuerttemberg stroke registry. BMC Neurology, 2016, 16, 222.	1.8	15
208	A collaborative sequential meta-analysis of individual patient data from randomized trials of endovascular therapy and tPA vs. tPA alone for acute ischemic stroke: <u>T</u> PA (TREAT) analysis: statistical analysis plan for a sequential meta-analysis performed within the VISTA-Endovascular collaboration.	5.9	13
209	International Journal of Stroke, 2015, 10, 136-144. Special topic section: linkages among cerebrovascular, cardiovascular, and cognitive disorders: Preventing dementia by preventing stroke: The Berlin Manifesto. International Journal of Stroke, 2019, , 174749301987191.	5.9	13
210	Critical Care and Emergency Medicine Neurology in Stroke. Stroke, 2005, 36, 205-207.	2.0	12
211	Intensive Care Management of Acute Stroke: Surgical Treatment. International Journal of Stroke, 2010, 5, 170-177.	5.9	12
212	Repeated Intra-Arterial Thrombectomy within 72 Hours in a Patient with a Clear Contraindication for Intravenous Thrombolysis. Case Reports in Vascular Medicine, 2015, 2015, 1-3.	0.2	12
213	Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial. Journal of the American Heart Association, 2015, 4, e001349.	3.7	12
214	Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registry. International Journal of Stroke, 2020, 15, 308-317.	5.9	12
215	Chapter 57 Thrombolytic therapy for acute stroke. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 94, 1155-1193.	1.8	11
216	Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial. Thrombosis Research, 2017, 156, 184-190.	1.7	11

#	Article	IF	CITATIONS
217	Implementing the Proclamation of Stroke and Potentially Preventable Dementias. International Journal of Stroke, 2018, 13, 780-786.	5.9	11
218	ECASS-II: intravenous alteplase in acute ischaemic stroke. Lancet, The, 1999, 353, 67-68.	13.7	10
219	Commentary on a GWAS: HDAC9 and the risk for ischaemic stroke. BMC Medicine, 2012, 10, 70.	5.5	10
220	The Results of the Recent Thrombectomy Trials May Influence Stroke Care Delivery: Are You Ready?. International Journal of Stroke, 2015, 10, 646-650.	5.9	10
221	Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K) Tj ETQq1 1 C Cardiology, 2017, 120, 1837-1840.).784314 r 1.6	gBT /Overlo
222	Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. International Journal of Cardiology, 2018, 257, 78-83.	1.7	10
223	Hemicraniectomy for space-occupying supratentorial ischemic stroke. Future Neurology, 2008, 3, 251-264.	0.5	9
224	(Here Comes that) Razors Edge Endovascular Stroke Therapy: The End, or Only the Beginning?. International Journal of Stroke, 2013, 8, 331-333.	5.9	9
225	Testing Devices for the Prevention and Treatment of Stroke and its Complications. International Journal of Stroke, 2014, 9, 683-695.	5.9	9
226	Stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia. Annals of Neurology, 2001, 49, 460-469.	5. 3	9
227	Regional and national differences in stroke thrombolysis use and disparities in pricing, treatment availability, and coverage. International Journal of Stroke, 2022, 17, 990-996.	5.9	9
228	Intravenous Thrombolysis is Effective in Young Adults: Results from the Baden-Wuerttemberg Stroke Registry. Frontiers in Neurology, 2015, 6, 229.	2.4	8
229	Selection for Delayed Intravenous Alteplase Treatment Based on a Prognostic Score. International Journal of Stroke, 2015, 10, 90-94.	5.9	8
230	Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. Journal of the American Heart Association, 2017, 6, .	3.7	8
231	Organizational Update. Stroke, 2017, 48, e341-e342.	2.0	8
232	Lack of International Consensus on Ethical Aspects of Acute Stroke Trials. Journal of Stroke and Cerebrovascular Diseases, 2012, 21, 200-204.	1.6	7
233	Early termination of THRILL, a prospective study of mechanical thrombectomy in patients with acute ischemic stroke ineligible for i.v. thrombolysis. Clinical Neuroradiology, 2016, 26, 499-500.	1.9	7
234	Professional guideline versus product label selection for treatment with IV thrombolysis: An analysis from SITS registry. European Stroke Journal, 2018, 3, 39-46.	5.5	7

#	Article	IF	CITATIONS
235	Implementing the proclamation of stroke and potentially preventable dementias. Journal of Clinical Hypertension, 2018, 20, 1354-1359.	2.0	7
236	Standards of practice in acute ischemic stroke intervention: International recommendations. Interventional Neuroradiology, 2019, 25, 31-37.	1.1	7
237	The King is Dead (Warfarin): Direct Thrombin and Factor Xa Inhibitors: The Next Diadochian War?. International Journal of Stroke, 2012, 7, 139-141.	5.9	6
238	Identification of imaging selection patterns in acute ischemic stroke patients and the influence on treatment and clinical trial enrollment decision making. International Journal of Stroke, 2016, 11, 180-190.	5.9	6
239	Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF. American Heart Journal, 2018, 200, 102-109.	2.7	6
240	Stroke: advances in therapy. Lancet Neurology, The, 2005, 4, 2.	10.2	5
241	Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R ₂ CHADS ₂ Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition) Tj ETQq1 1 0.78	84314 rgE 1.6	BT <u>f</u> Overlock
242	2013, 128, e172-3. Individual patient data meta-analysis of antiplatelet regimens after noncardioembolic stroke or TIA: rationale and design. International Journal of Stroke, 2015, 10, 145-150.	5.9	5
243	Thrombolysis in acute stroke – Authors' reply. Lancet, The, 2015, 385, 1396.	13.7	5
244	Diurnal Variation of Intravenous Thrombolysis Rates for Acute Ischemic Stroke and Associated Quality Performance Parameters. Frontiers in Neurology, 2017, 8, 341.	2.4	5
245	The impact of the DWI-FLAIR-mismatch in the ECASS-4 trial $\hat{a} \in A$ post hoc analysis. European Stroke Journal, 2020, 5, 370-373.	5.5	5
246	Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke. Stroke, 2021, 52, 3258-3265.	2.0	5
247	Thrombolytic Properties of Leukocytes from Peripheral Blood in Healthy Subjects and in Patients with Acute Cerebral Ischemia. Thrombosis Research, 2000, 98, 29-37.	1.7	4
248	Large and panhemispheric infarcts., 2001,, 490-498.		4
249	THE VERY ACUTE STROKE TREATMENT: FIBRINOLYSIS AND AFTER. Clinical and Experimental Hypertension, 2002, 24, 595-602.	1.3	4
250	Intraven�se Thrombolyse beim akuten Schlaganfall. Klinische Neuroradiologie, 2004, 14, 3-12.	0.9	4
251	Acute Ischemic Stroke Therapy. JAMA Neurology, 2015, 72, 1405.	9.0	4
252	Neurological research and practice: the first year. Neurological Research and Practice, 2020, 2, 5.	2.0	4

#	Article	IF	CITATIONS
253	Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF. American Heart Journal, 2021, 236, 4-12.	2.7	4
254	Decompressive Surgery for Malignant Middle Cerebral Artery Territory Infarction. Practical Neurology, 2002, 2, 144-154.	1.1	3
255	Acute endovascular recanalization. Current Opinion in Neurology, 2016, 29, 30-36.	3.6	3
256	Standards of Practice in Acute Ischemic Stroke Intervention International Recommendations. Canadian Journal of Neurological Sciences, 2019, 46, 269-274.	0.5	3
257	Embotrap Extraction & Examp; Clot Evaluation & Examp; Lesion Evaluation for NeuroThrombectomy (EXCELLENT) Registry design and methods. Journal of NeuroInterventional Surgery, 2022, 14, 783-787.	3.3	3
258	Current Trends in Therapy of Acute Ischaemic Stroke. Annals of Medicine, 1995, 27, 9-12.	3.8	2
259	Neurocritical Care for Acute Ischemic Stroke. Neurosurgery Clinics of North America, 1997, 8, 271-282.	1.7	2
260	"Self-Fulfilling Prophecy―or Recognition Requires a Concept of Perception. Stroke, 2000, 31, 231-239.	2.0	2
261	Author reply. Europace, 2014, 16, 151-152.	1.7	2
262	Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF. Cardiology and Therapy, 2019, 8, 283-295.	2.6	2
263	Letter to the Editor regarding the article â€Temporal trends in the accuracy of hospital diagnostic coding for identifying acute stroke: A population-based study' by Li L, Binney LE, Luengo-Fernandez R, Silver LW, Rothwell PM; on behalf of the Oxford Vascular Study. <i>European Stroke Journal </i> Oct 14. DO: 10.1177/2396987319881017. European Stroke Journal. 2020. 5. 104-105.	5.5	2
264	Zerebrale DurchblutungsstĶrungen: IschÄ#nische Infarkte. Springer-Lehrbuch, 2016, , 179-240.	0.0	2
265	Challenges for cerebrovascular disease. Frontiers in Neurology, 2010, 1, 3.	2.4	1
266	Selection of possible responders to thrombolytic therapy in acute ischemic stroke. Annals of the New York Academy of Sciences, 2012, 1268, 120-126.	3.8	1
267	Letter by Schönenberger et al Regarding Article, "Type of Anesthesia and Differences in Clinical Outcome After Intra-Arterial Treatment for Ischemic Stroke― Stroke, 2015, 46, e188.	2.0	1
268	Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation― Circulation, 2016, 134, e7-8.	1.6	1
269	World Stroke Day 2016 – "Face the facts: Stroke is treatable― International Journal of Stroke, 2016, 11, 844-845.	5.9	1
270	Organizational Update. Stroke, 2017, 48, e157-e158.	2.0	1

#	Article	IF	CITATIONS
271	Response to the growing dementia burden must be broader. Lancet Neurology, The, 2018, 17, 934.	10.2	1
272	Neurological research and practice: the first milestone has been reached. Neurological Research and Practice, 2021, 3, 3.	2.0	1
273	Systemic lymphoma in patients with the initial diagnosis of primary central nervous system lymphoma: a report of two cases. Journal of Neurology, 1999, 246, 855-857.	3.6	0
274	Critical Care Neurology., 2003,, 721-747.		0
275	Brain Embolism., 2003,, 373-391.		0
276	Response to Letter Regarding Article, "Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Disease― Circulation, 2010, 122, .	1.6	0
277	Good Times - Bad Times: My Story regarding Acute Stroke Treatment. Cerebrovascular Diseases, 2013, 36, 257-265.	1.7	0
278	Decompressive Craniectomy for Infarction and Hemorrhage. , 2016, , 1200-1217.		0
279	International Impact of <i>Stroke</i> . Stroke, 2020, 51, 1036-1039.	2.0	0
280	Thrombolysis for the Treatment of Acute Ischemic Stroke. Nosotchu, 2002, 24, 305-323.	0.1	0
281	Acute Ischemic Stroke., 2003,, 327-347.		0
282	Critical Care of the Patient with Acute Stroke. , 2004, , 987-1024.		0
283	Stroke management—The first 6 hours. Nosotchu, 2007, 29, 810-810.	0.1	0
284	MRI-based selection for thrombolysis beyond 3 hours. Nosotchu, 2007, 29, 573-577.	0.1	0
285	Cerebral Infarction. , 2011, , 1426-1439.		0
286	ZerebrovaskulÃre NotfÃte., 2011,, 655-667.		0
287	Critical Care of the Patient with Acute Stroke. , 2011, , 1008-1048.		0
288	IschÃ m ie des vorderen Kreislaufs. , 2012, , 369-390.		0

#	Article	IF	CITATIONS
289	ZerebrovaskulÃÆ NotfÃÆe., 2015, , 577-589.		0
290	ZerebrovaskulÃÆ NotfÃÆ., 2015, , 1-23.		0
291	A look back at 3Âyears of neurological research and practice (NRP). Neurological Research and Practice, 2022, 4, 19.	2.0	0